BR112019007309A2 - anticorpos anti-c1s e métodos de uso dos mesmos - Google Patents

anticorpos anti-c1s e métodos de uso dos mesmos

Info

Publication number
BR112019007309A2
BR112019007309A2 BR112019007309A BR112019007309A BR112019007309A2 BR 112019007309 A2 BR112019007309 A2 BR 112019007309A2 BR 112019007309 A BR112019007309 A BR 112019007309A BR 112019007309 A BR112019007309 A BR 112019007309A BR 112019007309 A2 BR112019007309 A2 BR 112019007309A2
Authority
BR
Brazil
Prior art keywords
antibodies
present disclosure
disclosure provides
methods
nucleic acids
Prior art date
Application number
BR112019007309A
Other languages
English (en)
Inventor
Parry Graham
E Stagliano Nancy
Panicker Sandip
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of BR112019007309A2 publication Critical patent/BR112019007309A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente descrição refere-se a anticorpos que ligam especificamente o componente da via do complemento c1s. a presente descrição fornece ácidos nucleicos compreendendo sequências de nucleotídeo que codificam os anticorpos anti-c1s; e células hospedeiras compreendendo os ácidos nucleicos. a presente descrição fornece composições compreendendo os anticorpos anti-c1s. a presente descrição fornece métodos de uso dos anticorpos anti-c1s.
BR112019007309A 2016-10-12 2017-10-12 anticorpos anti-c1s e métodos de uso dos mesmos BR112019007309A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407390P 2016-10-12 2016-10-12
PCT/US2017/056349 WO2018071676A1 (en) 2016-10-12 2017-10-12 Anti-c1s antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112019007309A2 true BR112019007309A2 (pt) 2019-07-02

Family

ID=61906346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007309A BR112019007309A2 (pt) 2016-10-12 2017-10-12 anticorpos anti-c1s e métodos de uso dos mesmos

Country Status (23)

Country Link
US (2) US20200048332A1 (pt)
EP (1) EP3525583A4 (pt)
JP (3) JP7069138B2 (pt)
KR (2) KR20240025715A (pt)
CN (2) CN110300520B (pt)
AR (1) AR110677A1 (pt)
AU (2) AU2017341766A1 (pt)
BR (1) BR112019007309A2 (pt)
CA (1) CA3040253A1 (pt)
CL (1) CL2019000975A1 (pt)
CO (1) CO2019004741A2 (pt)
CR (1) CR20190223A (pt)
DO (1) DOP2019000085A (pt)
EA (1) EA201990884A1 (pt)
EC (1) ECSP19033211A (pt)
IL (2) IL308156A (pt)
MX (1) MX2019004259A (pt)
PE (1) PE20191031A1 (pt)
PH (1) PH12019500789A1 (pt)
SG (1) SG11201903012RA (pt)
TN (1) TN2019000109A1 (pt)
TW (2) TWI773695B (pt)
WO (1) WO2018071676A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
US10729767B2 (en) 2015-04-06 2020-08-04 Bioverativ Usa Inc. Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage
JP2023522102A (ja) * 2020-04-20 2023-05-26 ジェンザイム・コーポレーション ヒト化抗補体Ｂｂ因子抗体およびその使用
BR112023001942A2 (pt) * 2020-08-06 2023-02-28 Bioverativ Usa Inc Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento
WO2023287573A2 (en) 2021-07-13 2023-01-19 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof
US20240117021A1 (en) 2022-06-15 2024-04-11 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
WO2023250507A1 (en) 2022-06-24 2023-12-28 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0911413A3 (en) 1992-12-03 2000-11-15 Genzyme Corporation Minimal adenovirus-based gene therapy vector
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
HUT76975A (hu) 1994-12-09 1998-01-28 Imperial College Innovations Limited Eljárás gének azonosítására
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
EP1041152A1 (en) 1996-10-17 2000-10-04 Oxford Biomedica (UK) Limited Retroviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
CA2467959C (en) 2001-11-09 2009-03-10 Robert M. Kotin Production of adeno-associated virus in insect cells
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
EP1697741A4 (en) * 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
EP2374817B1 (en) * 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7999032B2 (en) 2005-07-05 2011-08-16 Kaneka Corporation Methacrylic resin composition
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
CN101506369B (zh) 2006-06-21 2014-02-12 尤尼克尔生物制药股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav-rep78翻译起始密码子的载体
US7788398B2 (en) * 2007-08-08 2010-08-31 Swarmcast, Inc. Media player plug-in installation techniques
AU2009324092A1 (en) * 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
GB2509260B (en) * 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
CN105143261B (zh) * 2013-01-31 2021-04-09 首尔大学校产学协力团 C5抗体以及用于预防和治疗补体-相关的疾病的方法
PL3725803T3 (pl) * 2013-05-23 2022-04-04 Broteio Pharma B.V. Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
US10729767B2 (en) * 2015-04-06 2020-08-04 Bioverativ Usa Inc. Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage

Also Published As

Publication number Publication date
TW202246327A (zh) 2022-12-01
CL2019000975A1 (es) 2019-10-04
EA201990884A1 (ru) 2019-10-31
AU2017341766A1 (en) 2019-05-23
EP3525583A1 (en) 2019-08-21
US20200048332A1 (en) 2020-02-13
TN2019000109A1 (en) 2020-10-05
PE20191031A1 (es) 2019-08-05
KR20240025715A (ko) 2024-02-27
JP7069138B2 (ja) 2022-05-17
TWI773695B (zh) 2022-08-11
PH12019500789A1 (en) 2019-07-29
ECSP19033211A (es) 2019-07-31
CN116554320A (zh) 2023-08-08
CR20190223A (es) 2019-08-21
IL308156A (en) 2023-12-01
KR20190082783A (ko) 2019-07-10
DOP2019000085A (es) 2019-07-31
CN110300520A (zh) 2019-10-01
JP2022105114A (ja) 2022-07-12
CO2019004741A2 (es) 2019-07-31
US20240076363A1 (en) 2024-03-07
IL265957B2 (en) 2024-04-01
JP2024038319A (ja) 2024-03-19
AU2022205174A1 (en) 2022-09-29
CA3040253A1 (en) 2018-04-19
EP3525583A4 (en) 2020-06-10
JP2020502996A (ja) 2020-01-30
SG11201903012RA (en) 2019-05-30
CN110300520B (zh) 2022-10-04
WO2018071676A1 (en) 2018-04-19
JP7420864B2 (ja) 2024-01-23
TW201821437A (zh) 2018-06-16
AR110677A1 (es) 2019-04-24
IL265957A (en) 2019-05-30
IL265957B1 (en) 2023-12-01
KR102638884B1 (ko) 2024-02-22
MX2019004259A (es) 2019-09-27

Similar Documents

Publication Publication Date Title
BR112019007309A2 (pt) anticorpos anti-c1s e métodos de uso dos mesmos
BR112017021289A2 (pt) anticorpos anti-c1s humanizados e métodos de uso dos mesmos
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112016030908A2 (pt) moléculas com especificidade para cd45 e cd79
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
BR112018000604A2 (pt) moléculas de anticorpo que ligam cd45
BR112018007017A2 (pt) polipeptídeos
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112017003582A2 (pt) anticorpos, composições e usos
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112018073628A2 (pt) anticorpos antimiostatina e métodos de utilização
CR20180068A (es) Constructos de anticuerpo para cd70 y cd3
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
CL2020000937A1 (es) Anticuerpo multiespecífico.
CL2016000358A1 (es) Vacuna para adenovirus aviar
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112015023262B8 (pt) Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 1/02 , A61B 5/055 , A61K 39/395

Ipc: C07K 16/18 (2006.01), A61K 39/395 (2006.01), A61B

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]